$92.5M Series E Financing to Advance First-in-class Cyclin D1 Program CID-615 into Clinical Development Announced September 22, 2026
Target enrollment achieved in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma September 22, 2026
New Analyses Reinforcing Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC Announced September 22, 2026
Circle Pharma Announces $92.5 Million Series E Financing to Advance First-in-class Cyclin D1 Program into Clinical Development September 22, 2026
Ph 2 ALISCA®-Lung2 Trial of Alisertib + Paclitaxel Initiated for Patients with Advanced SCLC September 22, 2026
Lunsumio-based regimen significantly improves PFS in follicular lymphoma in Ph 3 CELESTIMO study September 22, 2026
MAA submitted to EMA for Lirafugratinib for Advanced/Metastatic Cholangiocarcinoma (CCA) Harboring FGFR2 Fusions or Rearrangements September 22, 2026
FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer September 22, 2026
NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Ph 2a Results September 22, 2026
Complete Full Cohort Ph 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent NSCLC Announced September 22, 2026
GX-BP1 Suppresses Tumor Regrowth despite Osimertinib and Dato-DXd Combination and Achieves 6/6 Complete Responses in Triple Combination September 22, 2026
Updated Data from Ph 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of BH-30643 in EGFR C797S-Positive NSCLC Presented September 22, 2026
